Losmapimod Protected Epileptic Rats From Hippocampal Neuron Damage Through Inhibition of the MAPK Pathway

Min Li†, Lexiang Cui†, Xuemin Feng†, Chao Wang†, Yinmeng Zhang‡, Lijie Wang§, Ying Ding* and Teng Zhao†*

†Department of Neurology, The First Hospital of Jilin University, Changchun, China, ‡Major in Clinical Medicine, Medical College of Nanchang University, Nanchang, China, §Department of Traditional Chinese Medicine, General Hospital of FAW, Fourth Hospital of Jilin University, Changchuan, China, *Department of Radiology, The First Hospital of Jilin University, Changchun, China

Objective: This research aimed to validate the therapeutic effect of losmapimod and explore the underlying mechanism in its treatment of epilepsy.

Methods: A rat model of epilepsy was constructed with an injection of pilocarpine. Microarray analysis was performed to screen aberrantly expressed mRNAs and activated signaling pathways between epileptic rats and normal controls. A TdT-mediated dUTP nick-end labeling (TUNEL) assay was used to identify cell apoptosis. Hippocampal cytoarchitecture was visualized with Nissl staining. The secretion of inflammatory factors as well as the marker proteins in the mitogen-activated protein kinase (MAPK) pathway were detected by Western blot. A Morris water maze navigation test evaluated the rats’ cognitive functions.

Results: Activation of the MAPK signaling pathway was observed in epilepsy rats. A decrease in the MAPK phosphorylation level by application of losmapimod protected against epilepsy by reducing neuron loss. Losmapimod effectively improved memory, reduced the frequency of seizures, protected the neuron from damage, and limited the apoptosis of neurons in epilepsy rats.

Conclusion: The application of losmapimod could partly reverse the development of epilepsy.

Keywords: losmapimod, mitogen-activated protein kinase, epilepsy, hippocampus, pilocarpine

INTRODUCTION

Epilepsy is a common neurological disorder, featuring an enduring predisposition to epileptic seizures due to hyperexcitability and hypersynchrony in brain neurons (Devinsky et al., 2013; Fisher et al., 2014) and affecting approximately 50 million people approximately worldwide, with a heavy burden brought on by individual complications, medical costs, related disability, and mortality (Moshe et al., 2015; Rana and Musto, 2018). Despite the application of antiepileptic drugs (AEDs) including phenobarbital, phenytoin sodium, carbamazepine, and sodium valproate in clinical therapy in the past decade, one third of epilepsies were still refractory, providing neither relief from...
epileptic seizures nor modification of epileptogenesis, resulting in an urgent need for effective drugs (Tadokoro et al., 1991; Perucca et al., 2007; Loscher and Schmidt, 2011).

Mitogen-activated protein kinases (MAPKs) consist of a family of protein–serine/protein–threonine kinases followed by proline, prevalent in mammals (Pearson et al., 2001), which can be activated by tyrosine kinase activity upstream through signal transduction (Oldenhof et al., 2002). As a pivotal biochemical cascade, the MAPK signaling pathway is involved in diverse fundamental events in cells and signal transduction pathways, namely, differentiation, proliferation, apoptosis, activation of other specific regulatory factors, acute responses to hormones, and developmental alteration of organisms (Pearson et al., 2001; Bandopadhyay et al., 2010; Gorter et al., 2014). Consequently, abnormalities in this pathway are disastrous, inducing various carcinomas such as colorectal cancer as well as neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and motor neuron diseases (Corcoran et al., 2012; Gorter et al., 2014), making the MAPK pathway a target for drug development (Kim and Choi, 2010).

Activated by stress, p38 MAPKs regulate vital cellular responses such as migration, contraction, cytokine production, and death in macrophages and myocardial and endothelial cells (Marber et al., 2010; Marber et al., 2011; Denise Martin et al., 2012; DeNicola et al., 2013). In myocardial injury models, inhibition of p38 MAPK decreased the infarction size (Ma et al., 1999; Li et al., 2006; Surinkaew et al., 2013), limited postinfarction remodeling, (See et al., 2004), and attenuated atherosclerosis progression (Seeger et al., 2010). In addition, the p38 MAPK inhibitor effectively shortened the duration of seizures in epileptic rats (Yang et al., 2018). Drion et al. (2018) also reported that curcumin could promote the phosphorylation of MAPK and influence the MAPK pathway in hippocampal sections of post-SE (status epilepticus) rats. The MAPK pathway also was reported to contributed to cognitive damage in pentylenetetrazole-induced epilepsy by downregulated levels of caspase 3 (Huang et al., 2017), and inhibition of the MAPK pathway reduces antiepileptic drug resistance in refractory epileptic rats (Shao et al., 2016). The p38MAPK signaling pathway participates in drug resistance in refractory epilepsy. Inhibition of p38 MAPK also suppressed the elevation of high-sensitivity C-reactive protein (hsCRP) concentrations after percutaneous coronary intervention (PCI) (Sarov-Blat et al., 2010).

As an inhibitor of p38 MAPK α and β isoforms, losmapimod was applied for acute coronary syndrome (ACS) and chronic obstructive pulmonary disease (Lomas et al., 2012; Ostenfeld et al., 2013). In cardiovascular disease, losmapimod attenuated vascular inflammation, concentrations of circulating hsCRP and interleukin-6 (Elkhawad et al., 2012), and, subsequently, enhanced vascular function in nitric oxide-dependent or -independent patients with untreated hypercholesterolemia (Cheriyan et al., 2011). A study of losmapimod-treated inflammation in other diseases like rheumatoid arthritis and neuropathy was also reported (Yang et al., 2013). However, whether losmapimod has an effect on epilepsy remains unclear.

In this paper, we investigated the protective role of losmapimod in epileptic rat hippocampal neurons. In addition, further study revealed the participation of the MAPK signaling pathway in the progression of epilepsy. Our study might provide a novel therapeutic strategy for epilepsy.

**METHODS AND MATERIALS**

**Microarray Analysis**

Gene expression profiling was conducted based on the GSE14763 microarray data from the GPL2896 microarray platform when rat hippocampi were subjected to pilocarpine immediately (or at least no later than 12 h) (Okamoto et al., 2010). Hippocampus tissues were collected immediately (up to 12 h) after the first spontaneous seizure (chronic). Differentially expressed genes were determined via the “limma” R package. Differentially expressed mRNAs in epilepsy with \[ \log_{2}(FC) > 2 \] and \[ P < 0.05 \] were screened.

**MRNA Processing by GSEA and STITCH**

Total mRNA expression data were uploaded to GSEA v3.0 software. Gene set enrichment analysis was conducted with the KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway gene set from the latest Kyoto Encyclopedia of Genes and Genomes database (http://www.genome.jp/kegg). Then, the seven most significant up/downregulation were screened out and underwent graphics processing via the “ggplot2” R package. In addition, the STITCH database was used as a resource to explore known and predicted interactions of chemicals and proteins, including direct (physical) and indirect (functional) associations. Default weighted enrichment statistics were adapted to process data 1,000 times with \[ P < 0.05 \] as the significance level.

**Cell Culture and Epileptiform Activity Induction**

Human hippocampal neurons (SHBIO, Shanghai, China) were divided into four groups (Ctrl, Ctrl + Los, epileptiform, and epileptiform + Los). Cells from the Ctrl group were incubated in 90% RPMI-1640 (HyClone) supplemented with 10% FBS (fetal bovine serum) at 37°C in a humidified, 5% CO2 atmosphere. A magnesium-free (MgF) physiological solution at pH 7.3 replaced the former medium for inducing epilepsy, containing (units in mM) 145 NaCl, 2.5 KCl, 10 glucose, and 0.001 glycine. Neurons in the epileptiform group were kept in MgF for 3 h. Neurons in the epileptiform + Los group were kept in MgF with 1 μM losmapimod for 3 h, and neurons in the Ctrl + Los group were kept in RPMI-1640 medium with 1 μM losmapimod for 3 h. After treatment, neurons were transferred to the conventional RPMI-1640 medium and maintained as previously described (Geng et al., 2018). Cells in the Ctrl group were maintained in RPMI-1640 medium under the same incubation conditions.

**Pilocarpine-Induced Status Epilepticus (SE)**

Animal assays were approved by the Animal Ethics Committee of the First Hospital of Jilin University. One hundred adult male
Sprague-Dawley rats aged 6–8 weeks and weighing 180–220 g were purchased from the National Institutes of Health (Bethesda, MD, USA), then randomly separated into control (30 rats) and SE (70 rats) groups. To prevent peripheral cholinergic pilocarpine effects, subcutaneous methylscopolamine (1 mg/kg, Sigma, St. Louis, MO, USA) was administered. Thirty minutes later, a pilocarpine (30 mg/kg; P6503; Sigma) intraperitoneal injection was administered to induce SE. Pilocarpine hydrochloride was given repeatedly (10 mg/kg, i.p.) every 30 min until the rats developed seizures. All rats that survived SE and presented spontaneous seizures after the silent period were considered epileptic. Rats in the control group were treated with lithium chloride and atropine sulfate as well, but the pilocarpine was replaced by normal saline. Finally, 57 SE rats were obtained, among which 45 were randomly sorted into three groups for further study. SE + Los (n = 15), SE + Pheno (n = 15), SE alone (n = 15), and control rats (n = 30) were intraperitoneally injected with losmapimod, phenobarbital, saline, and saline at 1.8 mg/kg, respectively, starting 4 h after SE and once daily for 3 days thereafter. Twenty-four hours after the last administration, three rats from each group were sacrificed to harvest their hippocampus tissues, and another 12 rats from each group were submitted to a Morris water maze (MWM) test.

Hippocampus Extraction
SE rats were anesthetized with isoflurane (Baxter Healthcare, Compton, UK), then sacrificed to obtain their brains, from which hippocampi were dissected on ice and sliced transversally at 400 μm with a McIlwain Tissue Chopper (Mickle Laboratories, Guildford, UK). Thereafter, slices were transferred to 30-mm-diameter membrane inserts (Millicell, Millipore) for further study. The remaining tissues were stored at −80°C.

Gene Expression Analysis
Total RNAs were isolated from tissue using TRizol Reagent (Invitrogen, Carlsbad, CA, USA). The concentration of RNA was measured using a Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA, USA), and cDNA from each sample was reverse transcribed using SuperScript VILO MasterMix (Life Technologies). Gene expression was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) using SYBR Premix Ex Taq II (Takara, Dalian, China). Fold change relative expression was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) using SYBR Premix Ex Taq II (Takara, Dalian, China). Fold change relative expression was calculated using the ΔΔCt method with one value that served as endogenous controls for mRNA analysis.

Western Blot
Proteins from the hippocampal tissue were extracted with RIPA lysis buffer (Beyotime, Institute of Biotechnology, Shanghai, China) following the manufacturer's instructions. The slides were then rinsed in distilled water, dehydrated by gradient concentrations of ethanol (70%, 80%, 90%, and 100%), cleared in xylene, and then added to the equilibration buffer. Next, the specimens were incubated with terminal deoxynucleotidyl transferase (TdT) and digoxigenin dNTPs for 60 min at 37°C followed by peroxidase-coupled anti-digoxigenin for 30 min at room temperature, then cultured in 3,3'-diaminobenzidine (DAB) substrate, counterstained with methyl green, rinsed, dehydrated, and mounted. A negative control without TdT was employed in case of nonspecific nucleotide interference or enzyme-conjugate binding. The average DAB staining intensity was considered as the apoptosis extent. Following four PBS washes, a mounting medium containing 0.5 μg/mL DAPI nuclear counterstain (Pierce, Rockford, IL, USA) was applied to the sections, and slides were coverslipped. Nine random fields were chosen by a blinded observer and used to quantify the apoptosis rate.
for 10% polyacrylamide gel (Boster Biological Technology) electrophoresis at 80 and 120 V. After that, wet transference was performed at 100 mV for 70 min on polyvinylidene fluoride (PVDF) membranes. Next, the membranes were blocked in 5% bovine serum albumin (BSA) at room temperature for 1 h, and primary antibodies anti-p38 (1:1,000, ab31828, Abcam, Cambridge, UK), anti-p38 (phospho T180 + Y182, 1:1,000, ab4822, Abcam), anti-β-actin (1:1,000, ab8227, Abcam), anti-IL-6 (1:1,000, ab9324, Abcam), anti-IL-1β (1:1,000, ab2105, Abcam), anti-IL-10 (1:1,000, ab34843, Abcam), anti-TNF-α (1:1,000, ab6671, Abcam), anti-CRP (1:1,000, ab50861, Abcam), anti-Bcl-2 (1:1,000, ab196495, Abcam), anti-Bax (1:1,000, ab53154, Abcam), and anti-cleaved caspase 3 (1:1,000, ab2302, Abcam) were added for incubation overnight at 4°C. Following Tris-buffered saline twen (TBST) washing for 5 min three times, secondary antibody IgG (1:1,000, ab150077, Abcam) was added at room temperature for 1-h incubation. After another washing for 5 min three times, immunoreactive proteins were detected by enhanced chemiluminescence (Thermo Fisher Scientific, Waltham, MA, USA) and analyzed by a Gel Dol EZ imager (Bio-Rad, Hercules, CA, USA). β-Actin served as a loading control. The gray value of each protein band was analyzed via ImageJ software. The experiments were run three times to calculate mean values.

Morris Water Maze
Forty-eight rats (12 rats from each group) were evaluated on their ability to locate a hidden platform to escape from water using a maze tank measuring 70 cm high and 180 cm in diameter where the stages were maintained at 2 cm below the water level in four labeled quadrants. Before the test, rats were allowed to adapt to the new environment for at least 30 min. The first part of the test, place navigation, was performed once a day from 9:00 to 11:00 am for four times consecutively, and a spatial probe was used on the fifth day as the second part of the test. To start the trial, rats were oriented toward the pool wall and placed into the water at different locations. They then had to swim to find the hidden stage in order to rest, and the length of time they stayed on the stage (escape latency) was recorded. Staying on the stage for no less than 2 s was recognized as the rat being well trained. If a rat failed, it would be guided to the stage by the experimenter and placed there for a certain length of time to determine a 2-min incubation period. On the fifth day, the hidden stage was removed, and rats were placed in the pool in the same way. The number of times that the rats crossed the removed stage and the duration of time spent at the location of the stage were recorded.

Observation Index
The Racine method of epileptic seizure classification was described in a previous study (Racine, 1972). According to this standard, the incubation period of epileptic seizures in rats was recorded for 10 min. The incubation period of epileptic seizure includes the incubation period of clonic cramps and the incubation period of tetanic convulsions. The transition time from clonic cramping to tetanic convulsions was calculated.

Statistical Analysis
GraphPad Prism 6.0 software was employed for the data analysis, expressing the results as the mean ± standard deviation (SD). Comparison of the data among all groups was analyzed by one-way ANOVA and between two groups by t-test. P < 0.05 was considered significant.

RESULTS
DEGs in Epilepsy and Related MAPK Signal Pathways
Based on microarray platform GPL2896 as well as microarray data GSE14763, differentially expressed genes were screened between healthy rats (n = 3) and epileptic rats (n = 5). Several of the most upregulated and downregulated mRNAs in the epilepsy group are presented in Figure 1A. The top seven activated pathways associated with the differentially expressed genes (DEGs) are presented in Figure 1B, including the MAPK signaling pathway. In addition, the losmapimod-interacted proteins were predicted by STITCH, among which MAPK14, MAPK11, and CPB showed the strongest association with losmapimod (Figure 1C).

The Effect of Losmapimod in Cell Apoptosis of Epileptiform Hippocampal Neurons
Cell apoptosis was higher in the epileptiform group than in the control groups, but losmapimod treatment rescued cell apoptosis in hippocampal neurons. The Ctrl + Los group behaved similarly as the Ctrl group (Figure 2A). To further verify this result, the expression of apoptotic proteins, such as Bax, Bcl2, and cleaved caspase 3, was also detected. Bax and cleaved caspase 3 were markedly upregulated in epileptiform hippocampal neurons, while Bcl2 was significantly downregulated. Losmapimod treatment obviously reversed the expression of Bax, Bcl2, and cleaved caspase 3 in epileptiform hippocampal neurons in vitro (Figure 2B). These data suggest that losmapimod treatment could reduce apoptosis in epileptiform neurons with no harm to normal cells.

Losmapimod Affects MAPK/NF-κB-Dependent Signaling and the Expression of Inflammatory Cytokines in Epileptiform Hippocampal Neurons
The expression of p-p38 was obviously upregulated in epileptiform hippocampal neurons compared with control neurons (Figure 3A). Losmapimod, a selective p38-α/β MAPK inhibitor, markedly inhibited the phosphorylation of p38 in epileptiform hippocampal neurons in vitro (Figure 3A). In addition, the expression of p-IκB was upregulated and IκB expression was markedly inhibited the phosphorylation of p38 in epileptiform hippocampal neurons compared with control neurons (Figure 3B). Losmapimod treatment significantly reversed this change. These
results suggest that MAPK/NF-κB-dependent signaling was involved in epileptiform hippocampal neurons after losmapimod treatment. Losmapimod also affected inflammatory responses in epileptiform hippocampal neurons. The levels of TNF-α, IL-1β, IL-6, IL-10, and CRP were all enhanced strikingly in epileptiform hippocampal neurons \((P < 0.05)\), and losmapimod treatment suppressed these indices and reversed their trends (Figure 3B).

Losmapimod Administration Restrained Pilocarpine-Induced Epilepsy

Neurons were degenerated in CA3 of pilocarpine-induced rats' hippocampi. Following losmapimod treatment, neuronal cell loss was inhibited compared with the SE group. In addition, the results of the losmapimod-treated group was similar to that of the phenobarbital-treated group (Figure 4A). These data suggest that losmapimod treatment could rescue the loss of neurons in the CA3 region. Cell apoptosis in the pilocarpine-induced epilepsy group was higher than that in the control group, but losmapimod treatment restrained apoptosis, though the effect was not as effective as it was with phenobarbital (Figure 4B). Bax and cleaved caspase 3 were upregulated, while Bcl2 was significantly downregulated in the hippocampal tissues of the SE rats. Losmapimod treatment significantly reversed the changes in Bax, Bcl2, and cleaved caspase 3 expression in hippocampal tissues \(in vivo\) (Figure 4C).

The expression of p-p38 and p-IκB was increased, and IκB expression was decreased in the hippocampal tissues of SE rats (Figure 5A). Losmapimod treatment obviously reduced p-p38 and p-IκB expression and enhanced IκB levels \(in vivo\) (Figure 5A). This result reveals that losmapimod could suppress the activation of the MAPK/NF-κB signaling pathway \(in vivo\). The levels of TNF-α, IL-1β, IL-6, IL-10, and CRP were all promoted remarkably in pilocarpine-induced epilepsy \((p < 0.05)\), and losmapimod treatment suppressed these indexes, similar to the effect of phenobarbital \((p < 0.05)\), as shown in Figure 5B.

NMDAR and AMPAR both play important roles in epilepsy. NMDA receptors (NMDARs) are hetero-oligomers composed of two NR1 subunits and one or more types of the NR2 subunit (A-D) (Wenthold et al., 2003). We found that the gene expressions
Losmapimod Protected Epilepsy via MAPK Pathway

Li et al. 2019 | Volume 10 | Article 625

Losmapimod Protected Epilepsy via MAPK Pathway

Losmapimod Ameliorated Cognitive Deficits in Pilocarpine-Induced Epilepsy

The incubation period and transition time of epileptic seizures were increased in the SE group compared with the control group. In addition, treatment with losmapimod increased the incubation period and transition time of epileptic seizures, which was the same effect seen with phenobarbital-treated SE rats (Table 1). To evaluate the cognitive effects of losmapimod, a Morris water maze test was performed. Figure 5A indicates that losmapimod reversed the changes caused by epilepsy in the rate of tetanic convulsions. Pretreatment for 4 days with losmapimod reduced the mean escape latency (P < 0.05), which was the same with phenobarbital in treating epilepsy, as illustrated in Figure 5B. Likewise, Figure 5C also indicates an evident elevation of mean path length in the epilepsy group compared to the control group (P < 0.05), which was obviously prevented after pretreatment with losmapimod and phenobarbital (P < 0.05). On the other hand, significant decreases in the time that the rats stayed in the target quadrant and in the times that the rats crossed the former stage were observed in the epilepsy group compared to the control group (P < 0.05), as shown in Figure 5D and E, respectively, indicating the spatial memory effect of losmapimod in SE rats. However, supplementation with losmapimod reversed the trend in pilocarpine-induced epilepsy.
rats during the probe trial \((P < 0.05)\). For swimming speed, no statistical significance was discovered among the groups, as shown in Figure 6F. Taken together, these findings strongly support the hypothesis that losmapimod may reverse the dysfunction of learning and memory in epileptic rats.

**DISCUSSION**

Recurrent seizure discharges, memory abnormality, and conscious impairment are some of the various syndromes in clinical epilepsy. The two most important complications of epileptic seizures are learning and memory deficits. Previous investigations have shown that the frequency of discharge in the electroencephalogram (EEG) during awake and sleep was more than 10\%, resulting in cognitive impairment in adult patients (Lv et al., 2013). Indeed, the longer the duration of the epilepsy, the more that cognition was impaired (Jokeit and Ebner, 1999).

In this article, we found that this cognition impairment can be reversed by the intraperitoneal injection of losmapimod and associate this phenomenon with neuronal apoptosis.

The MAPK signaling pathway was chosen to act as a link between epilepsy and apoptosis. In KEGG enrichment analysis, our results showed that the MAPK signaling path was activated in epileptic samples. MAPK was reported to be an important regulator of synaptic excitability, exerting an influence on cognitive impairment and epilepsy in animal models as well as human disease (Pernice et al., 2016). Xi et al. (2007) discovered the upregulation of MAPK in intractable epilepsy. It was demonstrated that the cognitive deficits in pentylentetrazole (PTZ)-induced epilepsy was associated with the abnormal expression of p38 MAPK (Huang et al., 2017). Huang et al. (2017) found that the expression of p-p38 was upregulated in a PTZ-induced epileptic model, which was similar to our study. Lopes et al. (2012) found the overexpression of p-p38 in the hippocampus and cortex of pilocarpine-induced epileptic rats, whereas decreased p38 activity...
was observed after kainic acid treatment in another study (Mielke et al., 1999), implying that p38 modifies the epileptogenic network.

Usually, cell apoptosis might be the terminal step of many signaling pathways, and thus, the relationship among apoptosis, epilepsy, and cognitive deficits has become a frequently researched topic over the last few decades (Mendez-Armenta et al., 2014; Teocchi and D’Souza-Li, 2016; Wang et al., 2016). For example, cognitive impairments and neuronal apoptosis were detected in epileptic patients and animal models (Jafarian et al., 2015; Zhang et al., 2017), suggesting their close link to epilepsy. In our
research, we also observed an increase in apoptosis in epileptic rats. However, losmapimod and phenobarbital both decreased neuronal cell loss, which might be an underlying reason for the losmapimod treatment of epilepsy.

Furthermore, Alam et al. reported that the behavioral effect of p38 was mediated by a reduction of cytokine production (Alam, 2015). The increased secretion of inflammatory factors exacerbated epileptic seizures (Das et al., 2012). Losmapimod, as an inhibitor of p38 MAPK, was expected to be effective in treating cytokine-dependent inflammatory diseases (Watz et al., 2014). In our research, we found that the protein expression of pro-inflammatory factors, including TNF-α, IL-1β, IL-6, and IL-10, was higher in pilocarpine-induced epilepsy. In addition, the treatment of losmapimod reversed these results. The activation of NF-κB-dependent signaling deteriorated

**FIGURE 5** Losmapimod upregulated p-p38 MAPK and decreased the activity of inflammatory cytokines in pilocarpine-induced epilepsy. (A) The protein expressions of p-p38, p38, p-IκB, and IκB were detected in hippocampal tissues of SE rats in vivo (n = 3). (B) IL-6, TNF-α, IL-1β, IL-10, and CRP levels were detected in hippocampal tissues of SE rats in vivo (n = 3). (C) NR1A, NR2A, NR2B, NR2C, and NR2D mRNAs were detected in hippocampus tissues of SE rats (n = 3). (D) GRIA1 and GRIA2 mRNAs were detected in hippocampus tissues of SE rats (n = 3). The data were normalized to the internal control, β-actin. Each sample was measured in triplicate. Data are all presented as the mean ± SD. *P < 0.05, **P < 0.01 vs. Ctrl, *P < 0.05 vs. SE group.
cognitive dysfunction and promoted neuronal apoptosis (Zhang et al., 2013). In our research, NF-κB-dependent signaling was activated in SE rats, and losmapimod treatment may alleviate SE pilocarpine-induced epilepsy by inhibiting the activation of MAPK/NF-κB-dependent signaling.

It was reported that the serum level of CRP was upregulated in epileptic patients and could be a biomarker for epileptic patients (Talaat et al., 2015; Zhou et al., 2018). CRP is an important molecule

| Group   | Incubation period of clonic cramp (s) | Transition time (s) | Incubation period of tetanic convulsion |
|---------|--------------------------------------|---------------------|----------------------------------------|
| Control | N.A.                                 | N.A.                | N.A.                                   |
| SE      | 63.7±18.1                            | 27.1±12.6           | 92.1±31.7                              |
| Los     | 92.8±36.6                            | 40.1±19.9           | 126.9±48.6                             |
| Pheno   | 94.1±43.6                            | 38.3±21.7           | 137.1±50.2                             |

**TABLE 1 | The effect of losmapimod on the seizure latency of epileptic rats.**

**FIGURE 6 | Profiles of behavioral testing by Morris water maze.** (A) The rate of tetanic convulsions, (B) escape latency, (C) mean path length, (D) percentage of time spent in the target quadrant, (E) number of times the platform was crossed, and (F) swimming speed in each group (n = 12). **P < 0.01 vs. Ctrl, #P < 0.05 vs. SE group. Ctrl: control, SE: pilocarpine-induced status epilepsy, SE + Los: epilepsy treated by losmapimod, SE + Pheno: epilepsy treated by phenobarbital.
related to the acute phase of the inflammatory process, the main effect of which is the modulation of several cascades related to immune system activation (Gewurz et al., 1995). IL-6 is the principal inducer of CRP gene expression, while IL-1, TNF-α, and activated complement act synergistically with IL-6 to enhance its effect (Ganapathi et al., 1991; Szalai et al., 2000). In our study, the expression of CRP was upregulated in the hippocampal tissue of SE rats, and losmapimod treatment partially reversed this change.

Ionotropic glutamate receptors (iGluRs) mediate the synaptic and metabolic actions of glutamate. These iGluRs are classified into the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type, kainate-type, and N-methyl-D-aspartate (NMDA)-type functional receptor families. NMDAR activation plays a pivotal role in the pathophysiology of several neurological disorders, such as hypoxia-ischemia, trauma, and epilepsy (Olney, 1990). In addition to NMDAR, AMPAR also plays an important role in epilepsy (Gross, 2019). In our study, NMDAR and AMPAR gene expressions were found to be upregulated in the hippocampal tissue of epilepsy rats. Losmapimod treatment could reverse NMDAR and AMPAR (specifically GRIA2) expressions, which indicated that losmapimod may protect against epilepsy through regulating synaptic protein distribution.

It is worth noting that several inadequacies in our findings were not neglectable. Since p38 MAPK participates in various cellular processes including cell growth, apoptosis, and cytokine production (Peluso et al., 2017), as an inhibitor, losmapimod should also have an effect on multiple systems in addition to the abovementioned. For example, hippocampal tissue contains not only neurons but also microglial cells and astrocytes that can also produce cytokines.

The internal relationship between cell and cell and between cell and losmapimod is therefore a new target for future research. In this study, only male rats were employed, which limits our conclusions as there are sex differences in seizure types and symptoms.

In conclusion, losmapimod could protect hippocampal neurons in epileptic rats by reducing hippocampal neuronal cell loss and inflammation secretion, resulting in relieving the symptoms of epilepsy in rats.

**ETHICS STATEMENT**

Animal assays were approved by the Animal Ethics Committee of the First Hospital of Jilin University.

**AUTHOR CONTRIBUTIONS**

ML, LC, XF, and CW provided substantial contribution to the conception and design of the work. CW, YZ, and LW performed analysis and interpretation of the data. ML drafted the manuscript. YD and TZ revised the work critically. Final approval of the work was done by all authors.

**FUNDING**

This work was supported by the UCB foundation project of epilepsy research fund of the Chinese Antiepileptic Association (2019030).

**REFERENCES**

Alam, J. J. (2015). Selective brain-targeted antagonism of p38 MAPKalpha reduces hippocampal IL-1beta levels and improves morris water maze performance in aged rats. *J. Alzheimers Dis.* 48, 219–227. doi: 10.3233/JAD-150277

Bandyopadhyay, S., Chiang, C. Y., Srivastava, J., Gersten, M., White, S., Bell, R., et al. (2016). A human MAP kinase interactome. *Nat. Methods* 7, 801–805. doi: 10.1038/nmeth.1506

Cheriyyan, J., Webb, A. J., Sarov-Blat, L., Elkhawad, M., Wallace, S. M., Maki-Petaja, K. M., et al. (2011). Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. *Circulation* 123, 515–523. doi: 10.1161/CIRCULATIONAHA.110.971986

Coras, R., and Blumcke, I. (2015). Clinico-pathological subtypes of hippocampal sclerosis in temporal lobe epilepsy and their differential impact on memory impairment. *Neuroscience* 309, 153–161. doi: 10.1016/j.neuroscience.2015.08.003

Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., et al. (2012). EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. *Cancer Discov.* 2, 227–235. doi: 10.1158/2159-8290.CD-11-0341

Das, A., Wallace, G. C., Holmes, C., McDowell, M. L., Smith, J. A., Marshall, J. D., et al. (2012). Hippocampal tissue of patients with refractory temporal lobe epilepsy is associated with astrocyte activation, inflammation, and altered expression of channels and receptors. *Neuroscience* 220, 237–246. doi: 10.1016/j.neuroscience.2012.06.002

DeNicola, G. F., Martin, E. D., Chaikuad, A., Bassi, R., Clark, J., Martino, L., et al. (2013). Mechanism and consequence of the autoactivation of p38alpha mitogen-activated protein kinase promoted by TAB1. *Nat. Struct. Mol. Biol.* 20, 1182–1190. doi: 10.1038/nsmb.2668

Denise Martin, E., De Nicola, G. F., and Marber, M. S. (2012). New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease. *Circulation* 126, 357–368. doi: 10.1161/CIRCULATIONAHA.111.071886

Devinsky, O., Zveznani, A., Najjar, S., De Lanerolle, N. C., and Rogawski, M. A. (2013). Glia and epilepsy: excitability and inflammation. *Trends Neurosci.* 36, 174–184. doi: 10.1016/j.tins.2012.11.008

Drion, C. M., van Scheppingen, J., Arena, A., Geijtenbeek, K. W., Kooijman, L., van Vliet, E. A., et al. (2018). Effects of rapamycin and curcumin on inflammation and oxidative stress in vitro and in vivo—in search of potential anti-epileptogenic strategies for temporal lobe epilepsy. *J. Neuroinflammation* 15, 212. doi: 10.1186/s12974-018-1247-9

Elkhawad, M., Rudd, J. H., Sarov-Blat, L., Cai, G., Wells, R., Davies, L. C., et al. (2012). Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. *JACC Cardiovasc. Imaging* 5, 911–922. doi: 10.1016/j.jcim.2012.02.016

Fisher, R. S., Acevedo, C., Arztmanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., et al. (2014). ILAE official report: a practical clinical definition of epilepsy. *Epilepsia* 55, 475–482. doi: 10.1111/epi.12550

Ganapathi, M. K., Rzewnicki, D., Samols, D., Jiang, S. L., and Kushner, I. (1991). Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. *J. Immunol.* 147, 1261–1265.

Geng, J. F., Liu, X., Zhao, H. B., Fan, W., Geng, J. J., and Liu, X. Z. (2018). LncRNA UCA1 inhibits epilepsy and seizure-induced brain injury by regulating miR-495/Nr2f-ARE signal pathway. *Int. J. Biochem. Cell Biol.* 99, 133–139. doi: 10.1016/j.biocel.2018.03.021

Gewurz, H., Zhang, X. H., and Lint, T. F. (1995). Structure and function of the pentraxins. *Curr. Opin. Immunol.* 7, 54–64. doi: 10.1016/0952-7915(95)80029-8
Okamoto, O. K., Janjoppi, L., Bonone, F. M., Pansani, A. P., da Silva, A. V., Moshe, S. L., Perucca, E., Ryvlin, P., and Tomson, T. (2015). Epilepsy: new advances. Lancet 385, 884–898. doi:10.1016/S0140-6736(14)00456-6
Okamoto, O. K., Janjoppi, L., Bonone, F. M., Pansani, A. P., da Silva, A. V., Scora, F. A., et al. (2010). Whole transcriptome analysis of the hippocampus toward a molecular portrait of epileptogenesis. BMC Genomics 11, 230. doi:10.1186/1471-2164-11-230
Oldenhof, A. D., Shynlova, O. P., Liu, M., Langille, B. L., and Lye, S. J. (2002). Mitogen-activated protein kinases mediate stretch-induced c-fos mRNA expression in myometrial smooth muscle cells. Am. J. Physiol. Cell Physiol. 283, C1530–1539. doi:10.1152/ajpcell.00607.2001

Oneye, J. W. (1990). Excitotoxic amino acids and neuropyschiatric disorders. Annu. Rev. Pharmacol. Toxicol. 30, 47–71. doi:10.1146/annurev.pa.30.020190.000403
Ostenfeld, T., Krivien, A., Lai, R. Y., Bullman, J., Baines, A. J., Green, J., et al. (2013). Analogic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study. Eur. J. Pain. 17, 844–857. doi:10.1002/ejp.2149.2012.00256.x
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B. E., Karandikar, M., Berman, K., et al. (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22, 153–183. doi:10.1210/edrv.22.2.0428
Peluso, L., Ylar, N. S., Ambra, R., Pastore, G., and Perry, G. (2017). MAPK signalling pathway in cancers: olive products as cancer preventive and therapeutic agents. Semin. Cancer Biol. 17, 3016S–30167. doi:10.1016/j.semcancer.2017.09.002
Pernice, H. F., Schieweck, R., Kiebler, M. A., and Popper, B. (2016). mTOR and MAPK: from localized translation control to epilepsy. BMC Neurosci. 17, 73. doi:10.1186/s12868-016-0308-1
Perucca, E., French, J., and Bialer, M. (2007). Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 6, 793–804. doi:10.1016/S1474-4422(07)70215-6
Racine, R. J. (1972). Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 32, 281–294. doi:10.1016/0013-4694(72)90177-8
Rana, A., and Musto, A. E. (2018). The role of inflammation in the development of epilepsy. J. Neuroinflammation 15, 144. doi:10.1186/s12974-018-1192-7
Sarov-Blat, L., Morgan, J. M., Fernandez, P., James, R., Fang, Z., Hurle, M. R., et al. (2010). Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans. Arterioscler. Thromb. Vasc. Biol. 30, 2256–2263. doi:10.1161/ATVBAHA.110.209205
See, F., Thomas, W., Way, K., Tzianidis, A., Kompa, A., Lewis, D., et al. (2004). p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J. Am. Coll. Cardiol. 44, 1679–1689. doi:10.1016/j.jacc.2004.07.038
Seeger, F. H., Sedding, D., Langheinrich, A. C., Haendeler, J., Zeiher, A. M., and Dimmeler, S. (2010). Inhibition of the p38 MAPK kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res. Cardiol. 105, 389–397. doi:10.1007/s00395-009-0072-9
Shao, Y., Wang, C., Hong, Z., and Chen, Y. (2016). Inhibition of p38 mitogen-activated protein kinase signaling reduces multidrug transporter activity and anti-epileptic drug resistance in refractory epileptic rats. J. Neurochem. 136, 1096–1105. doi:10.1111/jn.13498
Surinkaw, S., Kumphene, S., Chattipakorn, S., and Chattipakorn, N. (2013). Inhibition of p38 MAPK during ischemia, but not reperfusion, effectively attenuates fatal arrhythmia in ischemia/reperfusion heart. J. Cardiovasc. Pharmacol. 61, 133–141. doi:10.1097/JFC.0b013e318279b7b1
Szalai, A. J., van Ginkel, F. W., Wang, Y., McGhee, J. R., and Volanakis, J. E. (2000). Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component. J. Immunol. 165, 1030–1035. doi:10.4049/jimmunol.165.2.1030
Takadokoro, K., Ohno, T., Takafuli, S., Nakajima, K., Suzuki, S., Yamamoto, K., et al. (1991). Topical thrombin-induced IgE-mediated anaphylaxis: RAST serum and skin test studies. J. Allergy Clin. Immunol. 88, 620–629. doi:10.1016/0091-6749(91)90156-I
Talaat, F. M., Kamel, T., Rabah, A. M., Ahmed, S. M., El-Jaafary, S. I., and Abdelaziz, A. (2014). Mitogen-activated protein kinase inhibition decreases cerebral infarction and reduces seizure damage in temporal lobe epilepsy-associated hippocampal sclerosis. Epilepsy Curr. 14, 291. doi:10.1016/j.epepsoc.2014.06.006
This work was supported by a grant from the National Institute of Neurological Disorders and Stroke (NINDS R01 NS040190.000403).
pulmonary disease: a randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 2, 63–72. doi: 10.1016/S2213-2600(13)70200-5 Wenthold, R. J., Prybylowksi, K., Standley, S., Sans, N., and Petralia, R. S. (2003). Trafficking of NMDA receptors. Annu. Rev. Pharmacol. Toxicol. 43, 335–358. doi: 10.1146/annurev.pharmac.43.100901.135803

Xi, Z. Q., Wang, X. F., He, R. Q., Li, M. W., Liu, X. Z., Wang, L. Y., et al. (2007). Extracellular signal-regulated protein kinase in human intractable epilepsy. Eur. J. Neurol. 14, 865–872. doi: 10.1111/j.1468-1331.2007.01777.x

Yang, S., Lukey, P., Beerahee, M., and Hoke, F. (2013). Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases. Clin. Pharmacokinet. 52, 187–198. doi: 10.1007/s40262-012-0025-6

Yang, Z., Wang, J., Yu, C., Xu, P., Zhang, J., Peng, Y., et al. (2018). Inhibition of p38 MAPK signaling regulates the expression of EAAT2 in the brains of epileptic rats. Front. Neurol. 9, 925. doi: 10.3389/fneur.2018.00925

Zhang, B., Zhang, J. W., Wang, W. P., Dong, R. F., Tian, S., and Zhang, C. (2017). Effect of lamotrigine on epilepsy-induced cognitive impairment and hippocampal neuronal apoptosis in pentylenetetrazole-kindled animal model. Synapse 71:e21945. doi: 10.1002/syn.21945

Zhang, J., Zhen, Y. F., Pu Bu Ci, R., Song, L. G., Kong, W. N., Shao, T. M., et al. (2013). Salidroside attenuates beta amyloid-induced cognitive deficits via modulating oxidative stress and inflammatory mediators in rat hippocampus. Behav. Brain Res. 244, 70–81. doi: 10.1016/j.bbr.2013.01.037

Zhou, T., Wang, N., Xu, L., Huang, H., Yu, C., and Zhou, H. (2018). Effects of carbamazepine combined with vitamin B12 on levels of plasma homocysteine, hs-CRP and TNF-alpha in patients with epilepsy. Exp. Ther. Med. 15, 2327–2332. doi: 10.3892/etm.2018.5698

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.